MatthewTDrakeMD

PubMed

• It is not "just a fracture".
  Peggy M Cawthon, Matthew Drake> ;JBMR Plus. 2024 May 1
• Optimising zoledronate treatment holiday duration without loss of fracture prevention.
  Matthew T Drake> ;The Lancet. Diabetes & Endocrinology. 2024 Apr 1
• Commentary on the endocrine society clinical practice guideline on the "treatment of hypercalcemia of malignancy in adults".
  Ghada El-Hajj Fuleihan, Matthew T Drake> ;Metabolism. 2023 Jun 1
• 3 citations
  Patient and Physician Decisional Factors Regarding Hypercalcemia of Malignancy Treatment: A Novel Mixed-Methods Study.
  Aya Bassatne, Mohammad H Murad, Thomas Piggott, Matthew T Drake, Maya Rahme, Ghada El-Hajj Fuleihan> ;The Journal of Clinical Endocrinology and Metabolism. 2023 Feb 15
• 3 citations
  A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on the Treatment of Hypercalcemia of Malignancy in Adults.
  Mohamed O Seisa, Bashar Hasan, Mohammed Firwana, Samer Saadi, Ahmed Mushannen, Sahrish H Shah, Noora S Rajjoub, Magdoleen H Farah, Larry J Prokop, Zhen Wang, Ghada El-...> ;The Journal of Clinical Endocrinology and Metabolism. 2023 Feb 15
• 10 citations
  Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline.
  Ghada El-Hajj Fuleihan, Gregory A Clines, Mimi I Hu, Claudio Marcocci, M Hassan Murad, Thomas Piggott, Catherine Van Poznak, Joy Y Wu, Matthew T Drake> ;The Journal of Clinical Endocrinology and Metabolism. 2023 Feb 15
• Tumour-induced osteomalacia: a rare cause of chronic pain and weakness.
  John T Nasr, Jack Tohme, Michael T Collins, Matthew T Drake, Iris R Hartley, Jad Sfeir, Keith Dockery, Metin Taskin> ;Practical Neurology. 2022 Dec 1
• 3 citations
  Enhancing the Trustworthiness of the Endocrine Society's Clinical Practice Guidelines.
  Christopher R McCartney, Maureen D Corrigan, Matthew T Drake, Ghada El-Hajj Fuleihan, Mary T Korytkowski, Robert W Lash, David C Lieb, Anthony L McCall, Ranganath Muni...> ;The Journal of Clinical Endocrinology and Metabolism. 2022 Jul 14
• 23 citations
  Skeletal Aging.
  Jad G Sfeir, Matthew T Drake, Sundeep Khosla, Joshua N Farr> ;Mayo Clinic Proceedings. 2022 Jun 1
• Editorial - Cancer and Bone special issue.
  Claire M Edwards, Matthew T Drake> ;Bone. 2022 May 1
• 1 citations
  Pros and Cons of Skeletal Medications in the COVID-19 Era.
  Elena Tsourdi, Matthew T Drake> ;Current Treatment Options in Rheumatology. 2022 Jan 1
• Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal Outcome.
  Eli Muchtar, Matthew T Drake, Nelson Leung, Angela Dispenzieri, Martha Q Lacy, Francis K Buadi, David Dingli, Suzanne R Hayman, Prashant Kapoor, Yi Lisa Hwa, Amie Fond...> ;Frontiers in Endocrinology. 2022 Jan 1
• 9 citations
  Antidiabetic Effects of the Senolytic Agent Dasatinib.
  Omid Salaami, Chia-Ling Kuo, Matthew T. Drake, George A. Kuchel, James L. Kirkland, Robert J. Pignolo> ;Mayo Clinic Proceedings. 2021 Oct 21
• 5 citations
  Update on Approved Osteoporosis Therapies Including Combination and Sequential Use of Agents.
  Dominik Saul, Matthew T. Drake> ;Endocrinology and Metabolism Clinics of North America. 2021 Jun 1
• 11 citations
  Vaccination for Coronavirus Disease 2019 (COVID-19) and Relationship to Osteoporosis Care: Current Evidence and Suggested Approaches.
  Elena Tsourdi, Elaine W. Yu, Suzanne M. Jan de Beur, Matthew T. Drake> ;Journal of Bone and Mineral Research. 2021 Apr 8
• 2 citations
  Preoperative Imaging in Renal Transplant Patients with Tertiary Hyperparathyroidism
  Megan G. Berger, T. K. Pandian, Melanie L. Lyden, Travis J. McKenzie, Matthew T. Drake, Benzon M. Dy> ;World Journal of Surgery. 2021 Mar 27
• 80 citations
  Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group.
  Evangelos Terpos, Elena Zamagni, Suzanne Lentzsch, Matthew T. Drake, Ramón García-Sanz, Niels Abildgaard, Ioannis Ntanasis-Stathopoulos, Fredrik Schjesvold, Javier de ...> ;The Lancet. Oncology. 2021 Mar 1
• 2 citations
  Optimizing DXA to Assess Skeletal Health: Key Concepts for Clinicians
  Kurt A. Kennel, Jad G Sfeir, Matthew T. Drake> ;The Journal of Clinical Endocrinology and Metabolism. 2020 Dec 1
• 41 citations
  Determinants of Bone Material Strength and Cortical Porosity in Patients with Type 2 Diabetes Mellitus.
  Parinya Samakkarnthai, Jad G Sfeir, Elizabeth J. Atkinson, Sara J. Achenbach, Paul W. Wennberg, Peter J. Dyck, Amanda J Tweed, Tammie L Volkman, Shreyasee Amin, Joshua...> ;The Journal of Clinical Endocrinology and Metabolism. 2020 Oct 1
• Reply to Corticosteroid-Induced Osteonecrosis in COVID-19: A Call for Caution.
  Elaine W. Yu, Elena Tsourdi, Bart L. Clarke, Douglas C. Bauer, Matthew T. Drake> ;Journal of Bone and Mineral Research. 2020 Oct 1
• 12 citations
  Defining Very High Fracture Risk: Is FRAX Fit for Purpose?
  Juliet E Compston, Matthew T. Drake> ;Journal of Bone and Mineral Research. 2020 Aug 1
• 5 citations
  Use of trabecular bone score for risk stratification of patients with monoclonal gammopathy of undetermined significance
  Jad G Sfeir, Tito Pena Guzman, Lucia Bedatsova, Stephen M. Broski, Matthew T. Drake> ;Bone. 2020 Aug 1
• 66 citations
  Osteoporosis Management in the Era of COVID-19.
  Elaine W. Yu, Elena Tsourdi, Bart L. Clarke, Douglas C. Bauer, Matthew T. Drake> ;Journal of Bone and Mineral Research. 2020 Jun 1
• 8 citations
  Development and Application of Mass Spectroscopy Assays for Nε-(1-Carboxymethyl)-L-Lysine and Pentosidine in Renal Failure and Diabetes.
  Katherine L O'Grady, Sundeep Khosla, Joshua N. Farr, Olga P. Bondar, Elizabeth J. Atkinson, Sara J. Achenbach, Brittany A. Eckhardt, Brianne S Thicke, Amanda J Tweed, ...> ;The Journal of Applied Laboratory Medicine. 2020 May 1
• 6 citations
  Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic
  Aishwarya Ravindran, Kandace A. Lackore, Amy E. Glasgow, Matthew T. Drake, Miriam Hobbs, Taxiarchis Kourelis, Shaji Kumar, Robert A. Kyle, Nelson Leung, Eli Muchtar, R...> ;Mayo Clinic Proceedings. 2020 May 1
• Join now to see all

Journal Articles

• Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma  
  Inwards DJ, Fishkin PA, LaPlant BR, Drake MT, Kurtin PJ, Nikcevich DA, Wender DB, Lair BS, Witzig TE, Ann Oncol, 7/1/2014
• Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal women  
  Drake MT, McCready LK, Hoey KA, Atkinson EJ, Khosla S, Obstet Gynecol Surv, 5/1/2011
• Corrigendum to "Circulating osteogenic cells: Characterization and relationship to rates of bone loss in postmenopausal women"  
  Undale A, Srinivasan B, Drake M, McCready L, Atkinson E, Peterson J, Riggs BL, Amin S, Modder UI, Khosla S, Bone, 1/1/2011
• The use of biochemicalmarkers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group  
  Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescio R, Tosi P, Garcia-Sanz R, Davies F, Chanan-Khan A, Palumbo A, Sonneveld P, Drake MT, Harousseau JL, A..., Leukemia, 10/1/2010
• Vitamin D deficiency in multiple myeloma  
  Drake MT, Ng AC, European journal of Clinical and Medical Oncology, 1/1/2010
• ADP-ribosylation factor 1 dependent clathrin-coat assembly on synthetic liposomes  
  Zhu Y, Drake MT, Kornfeld S, Proc Natl Acad Sci U S A, 4/27/1999
• Join now to see all

Books/Book Chapters

• Multiple myeloma: diagnosed and treatment. 
  Chapter: Myeloma bone disease. 
  Page 211 - 223Drake MTEditors: Gertz MA; Rajkumar SV.Springer, New York, NY2014
• Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 
  Chapter: The Role of Sex Steroids in the Pathogenesis of Osteoporosis. 
  Page 367 - 375Drake MT, Khosla SEdition 8tj,2013
• Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism 
  Chapter: Role of sex steroids in the pathogenesis of osteoporosis. 
  Page 208 - 213Drake MT, Khosla SEdition 7th,2009

Abstracts/Posters

• Controversies in Pharmaceutical Management of Osteoporosis Therapy
  Drake MT, American Association of Clinical Endocrinologists Annual Meeting, 5/1/2014
• Skeletal Structural Changes and Fracture Risk in Monoclonal Gammopathy of Undetermined Significance.
  Drake MT, Central Society for Clinical and Translational Research Annual Meeting, Chicago, IL, 4/1/2014
• Monoclonal Gammopathy Associated Bone Loss
  Drake MT, Dresden University Medical Center, Dresden, Germany, 4/1/2014
• Bone loss in monoclonal gammopathy of undetermined significance.
  Drake MT, Advances in Mineral Metabolism Annual Meeting, 4/1/2014
• Bone Mineral Metabolism in Chronic Kidney Disease
  Drake MT, Nephrology Update - West Lake Forum, Hangzhou, China, 3/1/2014
• The Clinical Spectrum of Hypophosphatasia.
  Drake MT, Soft Bones Patient Education Meeting, San Diego, CA, 2/1/2014
• Circulating Sclerostin as a Marker of Bone Health and Disease
  Drake MT, Plenary Symposium American Society for Bone and Mineral Research Annual Meeting, 10/1/2013
• Osteoporosis in Men
  Drake MT, Endocrine Society Annual Meeting, San Francisco, CA, 6/1/2013
• Altered cortical microarchitecture and bone metabolism in patients with monoclonal gammopathy of undetermined significance.
  Drake MT, Zhang W, Kumar SK, Jacques R, Ng A, McCready LK, Rajkumar SV, Farr JN, 13th International Conference on Cancer Induced Bone Disease, 1/1/2013
• Altered cortical microarchitecture and bone metabolism in patients with monoclonal gammopathy of undetermined significance.
  Farr J Zhang W, Jacques R, Ng A, McCready L, Drake M, ASBMR Annual Meeting, 1/1/2013
• Isolation and characterization of human osteoblasts from needle biopsies without in vitro culture.
  Fujita K, Roforth M, Peterson J, Kirmani S, Drake M, McCready L, Monroe D, Khosla S, ASBMR Annual Meeting, 1/1/2013
• Estrogen reduces bone sost mRNA and circulating sclerostin levels in postmenopausal women.
  Roforth M, Fujita K, Demaray S, McGregor U, Kirmani S, McCready L, Peterson J, Drake M, David Monroe D, Khosla S, ASBMR Annual Meeting, 1/1/2013
• Suppression of osteoblastogenesis in human MSCs co-cultured with human multiple myeloma cells.
  Zhang W, Peterson J, Kassem M, Drake M, ASBMR Annual Meeting, 1/1/2013
• Phase I trial of rituximab, cladribine and temsirolimus (rct) for initial therapy of mantle cell lymphoma.
  Inwards DJ, Fishkin P, LaPlant BR, Drake MT, Kurtin P, Nikcevich D, Wender D, Lair B, Witzig TE, Blood, 11/1/2012
• Measurement of Sclerostin and DKK-1 in Serum: What Insights Has This Provided?
  Drake MT, European Calcified Tissue Society, Stockholm, Sweden, 5/1/2012
• Measurement of sclerostin and DKK-1 in serum: what insights has this provided?
  Drake M, Bone, 5/1/2012
• Bone Turnover Markers.
  Drake MT, Mayo Clinic Endocrine Course, Mallorca, Spain, 4/1/2012
• Skeletal Health in Cancer Patients
  Drake MT, Mayo Clinic Endocrine Course, Mallorca, Spain, 4/1/2012
• Zhang W, Dingli D, Russell S, Drake M, ASBMR Annual Meeting, 1/1/2012
• Hypophosphatasia Diagnosed in Adults: Differential Features Based on Sex, Presence of Fractures, and Symptoms at Presentation.
  Berkseth K, Tebben P, Drake M, Wermers R, J Bone Miner Res, 1/1/2012
• Skeletal Health Across the Monoclonal Gammopathy Spectrum.
  Drake MT, Washington University School of Medicine, St. Louis, MO, 12/1/2011
• Understanding Bone Disease Across the Monoclonal Gammopathy Spectrum.
  Drake MT, University of Arkansas Medical Sciences Winthrop P. Rockefeller Cancer Institute Grand Rounds, 2/1/2011
• Vitamin D levels in patients undergoing PBSCT.
  Zeldenrust S, Drake M, Gertz M, 13th International Myeloma Workshop, 1/1/2011
• Relationship of adiposity to volumetric BMD and microstructural parameters in men and women across the adult lifespan.
  Ng AC, Melton LJ, Atkinson EJ, Achenbach SJ, Drake MT, Khosla S, Amin S, Osteoporos Int, 12/1/2010
• Improving Quality of Care in the Treatment of Patients with Osteoporosis.
  Drake MT, Northern Michigan Regional Hospital Grand Rounds, Petoskey, MI, 11/1/2010
• Join now to see all

Lectures

• Monoclonal Gammopathy of Undetermined Significance (MGUS): Indications for Pre-Diagnostic Testing, Subsequent Diagnoses, and Follow-up Practice 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Optimizing Bone Health in Multiple Myeloma. 
  Atlanta, GA - 5/1/2014
• Monoclonal gammopathy-associated bone loss. 
  10/1/2013
• Management of Bone Disease in Multiple Myeloma. 
  Dallas, TX - 6/1/2011
• Suppression of FSH in postmenopausal women has no effect on bone resorption markers. 
  3/1/2011
• Join now to see all